Cover Image
市場調查報告書

原發性血小板增多症:全球臨床實驗趨勢

Essential Thrombocythemia Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 342277
出版日期 內容資訊 英文 122 Pages
訂單完成後即時交付
價格
Back to Top
原發性血小板增多症:全球臨床實驗趨勢 Essential Thrombocythemia Global Clinical Trials Review, H2, 2017
出版日期: 2017年08月17日 內容資訊: 英文 122 Pages
簡介

本報告提供原發性血小板增多症治療藥相關之臨床實驗調查分析,提供您最新趨勢,各階段及各方面狀況,有潛力的企業,正在開發的治療藥資訊,以及臨床實驗簡介等相關的系統性資訊。

目錄

報告指南

各地區的臨床實驗

  • 各國臨床實驗趨勢
    • 亞太地區的主要國家
    • 歐洲的主要國家
    • 北美的主要國家
    • 中東·非洲的主要國家
    • 中南美的主要國家

G7各國的臨床實驗:血液疾病臨床實驗上原發性血小板增多症的比例

G7各國的臨床實驗:各Phase

G7各國的臨床實驗:各階段

E7各國的臨床實驗:血液疾病臨床實驗上原發性血小板增多症的比例

E7各國的臨床實驗:各Phase

E7各國的臨床實驗:各階段

各方面的臨床實驗

各階段臨床實驗

評估項目別臨床實驗

未完成的臨床實驗

一定期間所採用的實驗對象

贊助商類別臨床實驗

有潛力的贊助商

  • 原發性血小板增多症的治療藥臨床實驗的主要參與企業

潛力藥物

臨床實驗簡介概要

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4455CTIDB

GlobalData's clinical trial report, "Essential Thrombocythemia Global Clinical Trials Review, H2, 2017" provides an overview of Essential Thrombocythemia clinical trials scenario. This report provides top line data relating to the clinical trials on Essential Thrombocythemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Essential Thrombocythemia to Oncology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Essential Thrombocythemia to Oncology Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Essential Thrombocythemia Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Clinical Trial Profile Snapshots 31

Appendix 120

  • Abbreviations 120
  • Definitions 120
  • Research Methodology 121
  • Secondary Research 121
  • About GlobalData 122
  • Contact Us 122
  • Disclaimer 122
  • Source 122

List of Tables

List of Tables

  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Essential Thrombocythemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Essential Thrombocythemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Essential Thrombocythemia Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Essential Thrombocythemia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Essential Thrombocythemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 15
  • Proportion of Essential Thrombocythemia to Oncology Clinical Trials, G7 Countries (%), 2017* 16
  • Essential Thrombocythemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Essential Thrombocythemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Essential Thrombocythemia to Oncology Clinical Trials, E7 Countries (%), 2017* 19
  • Essential Thrombocythemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Essential Thrombocythemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Essential Thrombocythemia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Essential Thrombocythemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Essential Thrombocythemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Essential Thrombocythemia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Essential Thrombocythemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Essential Thrombocythemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

List of Figures

  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Essential Thrombocythemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Essential Thrombocythemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Essential Thrombocythemia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Essential Thrombocythemia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Essential Thrombocythemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 15
  • Proportion of Essential Thrombocythemia to Oncology Clinical Trials, G7 Countries (%), 2017* 16
  • Essential Thrombocythemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Essential Thrombocythemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Essential Thrombocythemia to Oncology Clinical Trials, E7 Countries (%), 2017* 19
  • Essential Thrombocythemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Essential Thrombocythemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Essential Thrombocythemia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Essential Thrombocythemia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Essential Thrombocythemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Essential Thrombocythemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Essential Thrombocythemia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Essential Thrombocythemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Essential Thrombocythemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 121
Back to Top